Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluation
Abstract Tamoxifen is a commonly prescribed drug in both early and metastatic breast cancer. Prospective studies in Asian populations demonstrated that tamoxifen‐related liver steatosis occurred in more than 30% of the patients within 2 years after start of treatment. No well‐designed prospective st...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2022-09-01
|
| Series: | Hepatology Communications |
| Online Access: | https://doi.org/10.1002/hep4.2008 |
| _version_ | 1797705414159106048 |
|---|---|
| author | C. Louwrens Braal Robert J. deKnegt Agnes Jager Stijn L. W. Koolen Ron H. J. Mathijssen Karel Eechoute |
| author_facet | C. Louwrens Braal Robert J. deKnegt Agnes Jager Stijn L. W. Koolen Ron H. J. Mathijssen Karel Eechoute |
| author_sort | C. Louwrens Braal |
| collection | DOAJ |
| description | Abstract Tamoxifen is a commonly prescribed drug in both early and metastatic breast cancer. Prospective studies in Asian populations demonstrated that tamoxifen‐related liver steatosis occurred in more than 30% of the patients within 2 years after start of treatment. No well‐designed prospective studies on potential tamoxifen‐related liver steatosis have been conducted in Caucasian patients so far. Therefore, our prospective study aimed to assess the incidence of tamoxifen‐related liver steatosis for a period of 2 years in a population of Caucasian breast cancer patients treated with tamoxifen. Patients with an indication for adjuvant treatment with tamoxifen were included in this study. Data were collected at 3 months (T1) and at 2 years (T2) after start of tamoxifen treatment (follow‐up period of 21 months). For the quantification of liver steatosis, patients underwent liver stiffness measurement by transient elastography with simultaneous controlled attenuation parameter (CAP) determination using the FibroScan. A total of 95 Caucasian breast cancer patients were included in this evaluation. Liver steatosis was observed in 46 of 95 (48%) and 48 of 95 (51%) of the patients at T1 and T2, respectively. No clinically relevant increase in liver steatosis was observed during the treatment period of 2 years with tamoxifen (median CAP = 243 ± 49 dB/m (T1) and 253 ± 55 dB/m (T2), respectively; p = 0.038). Conclusion: In this prospective longitudinal study in Caucasian breast cancer patients, no clinically relevant alterations in liver steatosis in terms of CAP values and liver/lipid parameters were observed after 2 years of tamoxifen treatment. This study therefore demonstrates an absence of tamoxifen‐related adverse events such as steatosis and (early) development of fibrosis or cirrhosis during a treatment period of at least 2 years. |
| first_indexed | 2024-03-12T05:35:51Z |
| format | Article |
| id | doaj.art-ca1c7214505f4c0fbe363e19b2503695 |
| institution | Directory Open Access Journal |
| issn | 2471-254X |
| language | English |
| last_indexed | 2024-03-12T05:35:51Z |
| publishDate | 2022-09-01 |
| publisher | Wolters Kluwer Health/LWW |
| record_format | Article |
| series | Hepatology Communications |
| spelling | doaj.art-ca1c7214505f4c0fbe363e19b25036952023-09-03T06:27:24ZengWolters Kluwer Health/LWWHepatology Communications2471-254X2022-09-01692565256810.1002/hep4.2008Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluationC. Louwrens Braal0Robert J. deKnegt1Agnes Jager2Stijn L. W. Koolen3Ron H. J. Mathijssen4Karel Eechoute5Department of Medical Oncology Erasmus MC Cancer Institute Rotterdam The NetherlandsDepartment of Gastroenterology and Hepatology Erasmus University Medical Centre Rotterdam The NetherlandsDepartment of Medical Oncology Erasmus MC Cancer Institute Rotterdam The NetherlandsDepartment of Medical Oncology Erasmus MC Cancer Institute Rotterdam The NetherlandsDepartment of Medical Oncology Erasmus MC Cancer Institute Rotterdam The NetherlandsDepartment of Medical Oncology Erasmus MC Cancer Institute Rotterdam The NetherlandsAbstract Tamoxifen is a commonly prescribed drug in both early and metastatic breast cancer. Prospective studies in Asian populations demonstrated that tamoxifen‐related liver steatosis occurred in more than 30% of the patients within 2 years after start of treatment. No well‐designed prospective studies on potential tamoxifen‐related liver steatosis have been conducted in Caucasian patients so far. Therefore, our prospective study aimed to assess the incidence of tamoxifen‐related liver steatosis for a period of 2 years in a population of Caucasian breast cancer patients treated with tamoxifen. Patients with an indication for adjuvant treatment with tamoxifen were included in this study. Data were collected at 3 months (T1) and at 2 years (T2) after start of tamoxifen treatment (follow‐up period of 21 months). For the quantification of liver steatosis, patients underwent liver stiffness measurement by transient elastography with simultaneous controlled attenuation parameter (CAP) determination using the FibroScan. A total of 95 Caucasian breast cancer patients were included in this evaluation. Liver steatosis was observed in 46 of 95 (48%) and 48 of 95 (51%) of the patients at T1 and T2, respectively. No clinically relevant increase in liver steatosis was observed during the treatment period of 2 years with tamoxifen (median CAP = 243 ± 49 dB/m (T1) and 253 ± 55 dB/m (T2), respectively; p = 0.038). Conclusion: In this prospective longitudinal study in Caucasian breast cancer patients, no clinically relevant alterations in liver steatosis in terms of CAP values and liver/lipid parameters were observed after 2 years of tamoxifen treatment. This study therefore demonstrates an absence of tamoxifen‐related adverse events such as steatosis and (early) development of fibrosis or cirrhosis during a treatment period of at least 2 years.https://doi.org/10.1002/hep4.2008 |
| spellingShingle | C. Louwrens Braal Robert J. deKnegt Agnes Jager Stijn L. W. Koolen Ron H. J. Mathijssen Karel Eechoute Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluation Hepatology Communications |
| title | Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluation |
| title_full | Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluation |
| title_fullStr | Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluation |
| title_full_unstemmed | Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluation |
| title_short | Tamoxifen use and potential effects on liver parenchyma: A long‐term prospective transient elastographic evaluation |
| title_sort | tamoxifen use and potential effects on liver parenchyma a long term prospective transient elastographic evaluation |
| url | https://doi.org/10.1002/hep4.2008 |
| work_keys_str_mv | AT clouwrensbraal tamoxifenuseandpotentialeffectsonliverparenchymaalongtermprospectivetransientelastographicevaluation AT robertjdeknegt tamoxifenuseandpotentialeffectsonliverparenchymaalongtermprospectivetransientelastographicevaluation AT agnesjager tamoxifenuseandpotentialeffectsonliverparenchymaalongtermprospectivetransientelastographicevaluation AT stijnlwkoolen tamoxifenuseandpotentialeffectsonliverparenchymaalongtermprospectivetransientelastographicevaluation AT ronhjmathijssen tamoxifenuseandpotentialeffectsonliverparenchymaalongtermprospectivetransientelastographicevaluation AT kareleechoute tamoxifenuseandpotentialeffectsonliverparenchymaalongtermprospectivetransientelastographicevaluation |